BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:VIR-5500 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of VIR-5500\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05997615-11061@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:VIR-5500: Phase 1 readout est. (NCT05997615)
DESCRIPTION:VIR-5500\, phase 1\, Prostate Cancer.\nStudy: Safety\, Pharmaco
 kinetics\, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Canc
 er\nEstimated primary completion: 30 September 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/vir-5500#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05997615
URL:https://assetmemo.bio/drug/vir-5500#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
